Filing Details

Accession Number:
0001209191-18-056805
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-01 17:18:04
Reporting Period:
2018-11-01
Accepted Time:
2018-11-01 17:18:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1662394 Wayne Keith Ward 2801 Gateway Drive
Suite 150
Irving TX 75063
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2018-11-01 4,750 $0.00 4,750 No 4 C Direct
Class A Common Stock Disposition 2018-11-01 4,750 $59.48 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class B Common Stock Employee Stock Option (right to buy) Disposition 2018-11-01 4,750 $0.00 4,750 $11.62
Class A Common Stock Class B common stock Acquisiton 2018-11-01 4,750 $11.62 4,750 $0.00
Class A Common Stock Class B common stock Disposition 2018-11-01 4,750 $0.00 4,750 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,037 2023-06-15 No 4 M Direct
4,750 No 4 M Direct
0 No 4 C Direct
Footnotes
  1. The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017.
  2. The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $59.34 to $59.71. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  4. The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013.